Velarion · Company Intelligence
Compensation Brief
Fiscal year 2023 · Filings through 2025-06-03

bluebird bio (BLUE)

CEO Andrew Obenshain was paid $3,049,181 in fiscal year 2023, ↑ up 68.0% from fiscal year 2022 (SEC filing 0001293971-24-000049 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,049,181 ↑
Andrew Obenshain total, FY2023
—
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Andrew Obenshain (Chief Executive Officer), FY2023 total compensation $3,049,181 (base salary $681,657) [exec_comp, SEC accession 0001293971-24-000049, filed 2024-09-26]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

01

Summary Compensation Table — fiscal year 2023

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Andrew Obenshain$681,657$0$863,590$1,142,440$348,024$0$13,470$3,049,181
Chief Executive Officer
Richard Colvin489,8080281,050371,800187,425014,1701,344,253
Chief Medical Officer
Thomas Klima479,6150281,050371,800183,600013,4701,329,535
Chief Commercial and Operating Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2023 totalFY2022 totalFY2021 totalΔ FY2022→2023
Andrew Obenshain$3,049,181$1,814,700—↑ +1,234,481
Richard Colvin1,344,2531,364,776—↓ −20,523
Thomas Klima1,329,5351,247,251—↑ +82,284

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read bluebird bio's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper BLUE reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against BLUE
8 companies name BLUE as a compensation peer

Each company listed discloses BLUE in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named BLUE in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2023 total
Charlotte Jones-BurtonIndependent Director$146,406
Elisabeth LeidermanIndependent Director$167,906
John O. AgwunobiIndependent Director$160,906
Mark VachonChair of the Board$200,906
Michael CloonanIndependent Director—
Najoh Tita-ReidIndependent Director$153,906
Nick LeschlyIndependent Director$96,406
Richard PaulsonIndependent Director$65,238
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Andrew ObenshainDirector2025-01-06D140$9$1,294CommonForm 4 ↗
Richard ColvinChief Medical Officer2025-01-06D199176CommonForm 4 ↗
Joseph VittiglioChief Business & Legal Officer2025-02-03D23871,759CommonForm 4 ↗
Richard ColvinChief Medical Officer2025-02-03D647473CommonForm 4 ↗
Andrew ObenshainDirector2025-02-03D867636CommonForm 4 ↗
Thomas KlimaSee Remarks2025-02-03D1227902CommonForm 4 ↗
Andrew ObenshainDirector2025-02-10A76300CommonForm 4 ↗
Richard ColvinChief Medical Officer2025-03-03D58442,289CommonForm 4 ↗
Andrew ObenshainDirector2025-03-03D92143,610CommonForm 4 ↗
Thomas KlimaSee Remarks2025-03-03D50041,960CommonForm 4 ↗
Nick LeschlyDirector2025-05-30D6,150——CommonForm 4 ↗
Thomas KlimaSee Remarks2025-05-30D3,414——CommonForm 4 ↗
Najoh Tita-ReidDirector2025-05-30D1,163——CommonForm 4 ↗
Mark VachonDirector2025-05-30D1,252——CommonForm 4 ↗
Charlotte Jones-BurtonDirector2025-05-30D928——CommonForm 4 ↗
Elisabeth LeidermanDirector2025-05-30D1,112——CommonForm 4 ↗
Richard ColvinChief Medical Officer2025-05-30D3,552——CommonForm 4 ↗
Richard PaulsonDirector2025-05-30D155——CommonForm 4 ↗
Joseph VittiglioChief Business & Legal Officer2025-05-30D1,143——CommonForm 4 ↗
Andrew ObenshainDirector2025-05-30D9,027——CommonForm 4 ↗
Nick LeschlyDirector2025-05-30D2,284——CommonForm 4 ↗
Nick LeschlyDirector2025-05-30D14,416——CommonForm 4 ↗
John O. AgwunobiDirector2025-05-30D1,323——CommonForm 4 ↗
O. James SterlingChief Financial Officer2025-06-02D5,000——CommonForm 4 ↗
Richard ColvinChief Medical Officer2025-06-02A2,500——CommonForm 4 ↗
Joseph VittiglioChief Business & Legal Officer2025-06-02A2,500——CommonForm 4 ↗
Thomas KlimaSee Remarks2025-06-02D2,500——CommonForm 4 ↗
Thomas KlimaSee Remarks2025-06-02A2,500——CommonForm 4 ↗
Andrew ObenshainDirector2025-06-02A14,820——CommonForm 4 ↗
O. James SterlingChief Financial Officer2025-06-02D2,500——CommonForm 4 ↗
Thomas KlimaSee Remarks2025-06-02D4,464——CommonForm 4 ↗
Mark VachonDirector2025-06-02D1,245——CommonForm 4 ↗
John O. AgwunobiDirector2025-06-02D1,245——CommonForm 4 ↗
Joseph VittiglioChief Business & Legal Officer2025-06-02D2,500——CommonForm 4 ↗
Joseph VittiglioChief Business & Legal Officer2025-06-02D3,125——CommonForm 4 ↗
Michael CloonanDirector2025-06-02D1,867——CommonForm 4 ↗
O. James SterlingChief Financial Officer2025-06-02A2,500——CommonForm 4 ↗
Elisabeth LeidermanDirector2025-06-02D1,245——CommonForm 4 ↗
Najoh Tita-ReidDirector2025-06-02D1,245——CommonForm 4 ↗
Charlotte Jones-BurtonDirector2025-06-02D1,245——CommonForm 4 ↗
Andrew ObenshainDirector2025-06-02D14,820——CommonForm 4 ↗
Andrew ObenshainDirector2025-06-02D9,300——CommonForm 4 ↗
Richard ColvinChief Medical Officer2025-06-02D2,500——CommonForm 4 ↗
Richard PaulsonDirector2025-06-02D1,323——CommonForm 4 ↗
Richard ColvinChief Medical Officer2025-06-02D4,166——CommonForm 4 ↗
Nick LeschlyDirector2025-06-02D1,245——CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2023

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Andrew ObenshainPRSU—————$863,590
Thomas KlimaOption—————371,800
Andrew ObenshainOption—————1,142,440
Richard ColvinOption—————371,800
Thomas KlimaPRSU—————281,050
Richard ColvinPRSU—————281,050
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Andrew Obenshain$0$0$1,142,4400.0%
Thomas Klima00371,8000.0%
Richard Colvin00371,8000.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2023

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Richard ColvinRSU55,000—$75,900
Thomas KlimaRSU55,000—75,900
Andrew ObenshainRSU15,059—20,781
Richard ColvinOption43,7506.35—
Andrew ObenshainRSU27,000—37,260
Andrew ObenshainRSU100,387—138,534
Thomas KlimaRSU18,750—25,875
Richard ColvinRSU10,039—13,854
Andrew ObenshainRSU862—1,190
Richard ColvinRSU555—766
Andrew ObenshainRSU101,400—139,932
Richard ColvinRSU22,500—31,050
Andrew ObenshainRSU2,585—3,567
Richard ColvinRSU2,009—2,772
Andrew ObenshainOption18636.78—
Andrew ObenshainOption4,75626.45—
Andrew ObenshainOption16,33114.17—
Andrew ObenshainOption160,88812.76—
Andrew ObenshainOption48,7507.8—
Andrew ObenshainOption338,0005.11—
Thomas KlimaOption35,57315.5—
Thomas KlimaOption15,1266.55—
Richard ColvinOption2,19514.17—
Thomas KlimaRSU8,250—11,385
Thomas KlimaRSU25,096—34,632
Richard ColvinOption12436.78—
Richard ColvinOption110,0005.11—
Thomas KlimaOption110,0005.11—
Andrew ObenshainRSU67,600—93,288
Andrew ObenshainRSU13,500—18,630
Thomas KlimaOption27,0907.8—
Richard ColvinRSU9,975—13,766
Richard ColvinOption12,58014.99—
Richard ColvinOption14,3007.8—
05

Incentive-plan design — the Compensation Discussion & Analysis

bluebird bio's compensation program is designed to align executive interests with the drivers of growth and stockholder returns by supporting the Company's achievement of its primary business goals, while attracting and retaining employees whose talents and contributions are expected to sustain growth and drive long-term stockholder value. The Compensation Committee maintains an ongoing commitment to corporate governance principles and strong performance orientation, regularly reviewing compensation policies to ensure they are aligned with stockholder interests, business goals, and that total compensation is fair, reasonable, and competitive.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)—
Independent consultantAon plc (Human Capital Solutions practice)
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
08

Director compensation — fiscal year 2023

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Mark VachonIndependent · Board Chair · Audit · Compensation (Chair)$104,500$41,110$55,296—$0$200,906
Elisabeth LeidermanIndependent · Audit (Chair) · Compensation71,50041,11055,296—0167,906
John O. AgwunobiIndependent · Audit · Nominating/Governance (Chair)64,50041,11055,296—0160,906
Najoh Tita-ReidIndependent · Compensation · Nominating/Governance57,50041,11055,296—0153,906
Charlotte Jones-BurtonIndependent · Nominating/Governance50,00041,11055,296—0146,406
Nick LeschlyIndependent—41,11055,296—096,406
Richard PaulsonIndependent · Newly elected33,50015,38816,350—065,238
Andrew ObenshainEmployee director000—00
Michael CloonanIndependent · Newly elected000—00
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)10,000 / 15,000 / 10,000
Stock ownership guideline3x annual cash retainer for non-employee directors; 3x base salary for CEO
09b

Total cost of the board

ComponentFY2023
Cash retainers and fees$381,500
Equity awards (grant-date value)$262,048
All other compensation$0
Total cost of the board$643,548

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1bluebird bio2023Andrew Obenshain$681,657$863,590$1,142,440$348,024$3,049,181

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10d

Frequently asked questions

Who was the highest-paid executive at bluebird bio in fiscal 2023?
As disclosed, Andrew Obenshain (Chief Executive Officer) was the highest-paid executive at bluebird bio in fiscal 2023, with total compensation of $3,049,181.
How much does bluebird bio spend in total on board compensation for fiscal 2023?
As disclosed, bluebird bio reported total board compensation of $643,548 for fiscal 2023.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Andrew ObenshainDEF 14A2024-09-260001293971-24-000049Section “Summary Compensation Table”. As printed: 3,049,181. Filing ↗machine: r2 · c21 · span 402787–402796
2Section 01, Richard ColvinDEF 14A2024-09-260001293971-24-000049Section “Summary Compensation Table”. As printed: 1,344,253. Filing ↗machine: r6 · c21 · span 409492–409501
3Section 01, Thomas KlimaDEF 14A2024-09-260001293971-24-000049Section “Summary Compensation Table”. As printed: 1,329,535. Filing ↗machine: r4 · c21 · span 406139–406148
4Section 03, Andrew Obenshain PRSUDEF 14A2024-09-260001293971-24-000049Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t28 · r2 · c4 · span 402101–402108
5Section 03, Thomas Klima OptionDEF 14A2024-09-260001293971-24-000049Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t28 · r4 · c3 · span 405328–405335
6Section 03, Andrew Obenshain OptionDEF 14A2024-09-260001293971-24-000049Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t28 · r2 · c3 · span 401870–401879
7Section 03, Richard Colvin OptionDEF 14A2024-09-260001293971-24-000049Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t28 · r6 · c3 · span 408681–408688
8Section 03, Thomas Klima PRSUDEF 14A2024-09-260001293971-24-000049Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t28 · r4 · c4 · span 405531–405538
9Section 03, Richard Colvin PRSUDEF 14A2024-09-260001293971-24-000049Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t28 · r6 · c4 · span 408884–408891
10Section 08, Mark VachonDEF 14A2024-09-260001293971-24-000049Section “Director Compensation”. As printed: 200,906. Filing ↗machine: t37 · r3 · c10 · span 565722–565932
11Section 08, Elisabeth LeidermanDEF 14A2024-09-260001293971-24-000049Section “Director Compensation”. As printed: 167,906. Filing ↗machine: span 567165–567375
12Section 08, John O. AgwunobiDEF 14A2024-09-260001293971-24-000049Section “Director Compensation”. As printed: 160,906. Filing ↗machine: span 564240–564476
13Section 08, Najoh Tita-ReidDEF 14A2024-09-260001293971-24-000049Section “Director Compensation”. As printed: 153,906. Filing ↗machine: t37 · r5 · c10 · span 568598–568808
14Section 08, Charlotte Jones-BurtonDEF 14A2024-09-260001293971-24-000049Section “Director Compensation”. As printed: 146,406. Filing ↗machine: span 570051–570261
15Section 08, Nick LeschlyDEF 14A2024-09-260001293971-24-000049Section “Director Compensation”. As printed: 96,406. Filing ↗machine: t37 · r8 · c10 · span 573081–573290
16Section 08, Richard PaulsonDEF 14A2024-09-260001293971-24-000049Section “Director Compensation”. As printed: 65,238. Filing ↗machine: t37 · r7 · c10 · span 571488–571697
17Section 08, Andrew ObenshainDEF 14A2024-09-260001293971-24-000049Section “Director Compensation”. As printed: 0. Filing ↗
18Section 08, Michael CloonanDEF 14A2024-09-260001293971-24-000049Section “Director Compensation”. As printed: 0. Filing ↗
19Section 02, Andrew Obenshain 2025-01-06Form 42025-01-080001562180-25-000269Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Richard Colvin 2025-01-06Form 42025-01-080001562180-25-000270Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Joseph Vittiglio 2025-02-03Form 42025-02-050001562180-25-000951Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Richard Colvin 2025-02-03Form 42025-02-050001562180-25-000952Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Andrew Obenshain 2025-02-03Form 42025-02-050001562180-25-000950Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Thomas Klima 2025-02-03Form 42025-02-050001562180-25-000953Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Andrew Obenshain 2025-02-10Form 42025-02-120001562180-25-001152Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Richard Colvin 2025-03-03Form 42025-03-050001562180-25-002090Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Andrew Obenshain 2025-03-03Form 42025-03-050001562180-25-002088Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Thomas Klima 2025-03-03Form 42025-03-050001562180-25-002089Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Nick Leschly 2025-05-30Form 42025-06-030000950170-25-081115Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Thomas Klima 2025-05-30Form 42025-06-030000950170-25-081125Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Najoh Tita-Reid 2025-05-30Form 42025-06-030000950170-25-081150Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Mark Vachon 2025-05-30Form 42025-06-030000950170-25-081156Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Charlotte Jones-Burton 2025-05-30Form 42025-06-030000950170-25-081131Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Elisabeth Leiderman 2025-05-30Form 42025-06-030000950170-25-081135Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Richard Colvin 2025-05-30Form 42025-06-030000950170-25-081151Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Richard Paulson 2025-05-30Form 42025-06-030000950170-25-081108Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Joseph Vittiglio 2025-05-30Form 42025-06-030000950170-25-081175Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Andrew Obenshain 2025-05-30Form 42025-06-030000950170-25-081140Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Nick Leschly 2025-05-30Form 42025-06-030000950170-25-081115Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Nick Leschly 2025-05-30Form 42025-06-030000950170-25-081115Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, John O. Agwunobi 2025-05-30Form 42025-06-030000950170-25-081163Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, O. James Sterling 2025-06-02Form 42025-06-030000950170-25-081123Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Richard Colvin 2025-06-02Form 42025-06-030000950170-25-081151Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Joseph Vittiglio 2025-06-02Form 42025-06-030000950170-25-081175Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Thomas Klima 2025-06-02Form 42025-06-030000950170-25-081125Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Thomas Klima 2025-06-02Form 42025-06-030000950170-25-081125Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Andrew Obenshain 2025-06-02Form 42025-06-030000950170-25-081140Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, O. James Sterling 2025-06-02Form 42025-06-030000950170-25-081123Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Thomas Klima 2025-06-02Form 42025-06-030000950170-25-081125Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Mark Vachon 2025-06-02Form 42025-06-030000950170-25-081156Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, John O. Agwunobi 2025-06-02Form 42025-06-030000950170-25-081163Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Joseph Vittiglio 2025-06-02Form 42025-06-030000950170-25-081175Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Joseph Vittiglio 2025-06-02Form 42025-06-030000950170-25-081175Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Michael Cloonan 2025-06-02Form 42025-06-030000950170-25-081105Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, O. James Sterling 2025-06-02Form 42025-06-030000950170-25-081123Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Elisabeth Leiderman 2025-06-02Form 42025-06-030000950170-25-081135Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Najoh Tita-Reid 2025-06-02Form 42025-06-030000950170-25-081150Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Charlotte Jones-Burton 2025-06-02Form 42025-06-030000950170-25-081131Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Andrew Obenshain 2025-06-02Form 42025-06-030000950170-25-081140Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Andrew Obenshain 2025-06-02Form 42025-06-030000950170-25-081140Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Richard Colvin 2025-06-02Form 42025-06-030000950170-25-081151Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Richard Paulson 2025-06-02Form 42025-06-030000950170-25-081108Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Richard Colvin 2025-06-02Form 42025-06-030000950170-25-081151Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Nick Leschly 2025-06-02Form 42025-06-030000950170-25-081115Insider equity transaction reported since the proxy statement. Filing ↗
65Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
66Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
67Section 09b board cost (computed)Computed——Cash 381,500 + equity 262,048 + all other 0 = 643,548, summed across the director compensation table rows.machine: formula: Σ = 643,548
68bluebird bio (subject), Section 10b CEO totalDEF 14A2024-09-260001293971-24-000049CEO total compensation as printed in bluebird bio's own proxy. As printed: 3,049,181. Filing ↗machine: r2 · c21 · span 402787–402796

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.